66464-86-6

Basic information

• Product Name: 3-CHLOROPHENYLACETYLHYDRAZIDE
• Synonyms: 3-CHLOROPHENYLACETYLHYDRAZIDE;(3-CHLORO-PHENYL)-ACETIC ACID HYDRAZIDE;3-Chloro-benzeneacetic acid hydrazide;2-(3-CHLOROPHENYL)ACETOHYDRAZINE
• CAS NO: 66464-86-6
• Molecular Formula: C₈H₉ClN₂O
• Molecular Weight: 184.62
• Mol File: 66464-86-6.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 394.9 °C at 760 mmHg
• Flash Point: 192.6 °C
• Appearance: /
• Density: 1.283 g/cm³
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-CHLOROPHENYLACETYLHYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-CHLOROPHENYLACETYLHYDRAZIDE(66464-86-6)
• EPA Substance Registry System: 3-CHLOROPHENYLACETYLHYDRAZIDE(66464-86-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22-41
• Safety Statements: 26-39
• Hazardous Substances Data: 66464-86-6(Hazardous Substances Data)

Usage

General Description

3-CHLOROPHENYLACETYLHYDRAZIDE, also known as 3-chlorophenylacetylhydrazine, is a chemical compound with the molecular formula C8H9ClN2O. It is a white to off-white crystalline powder that is used as a reagent and intermediate in the synthesis of other organic compounds. 3-CHLOROPHENYLACETYLHYDRAZIDE has applications in the pharmaceutical industry, where it is used in the production of hydrazide derivatives of drugs, as well as in the manufacture of agricultural chemicals. It is also utilized in research and development laboratories for its potential medicinal and biocidal properties. However, it is important to handle this chemical with caution, as it may be harmful if ingested, inhaled, or absorbed through the skin, and proper safety measures should be followed when working with it.

Upstream product

• 53088-68-9 methyl 3-chlorophenylacetate 
• 1878-65-5 3-chlorophenylacetic acid 
• 14062-29-4 ethyl 2-(3-chlorophenyl)acetate 

Relevant articles and documents

Synthesis and structure-activity relationships of 3,4,5-trisubstituted-1,2,4-triazoles: High affinity and selective somatostatin receptor-4 agonists for Alzheimer's disease treatment

Somatostatin receptor-4 (SST4) is highly expressed in brain regions affiliated with learning and memory. SST4 agonist treatment may act to mitigate Alzheimer's disease (AD) pathology. An integrated approach to SST4 agonist lead optimization is presented herein. High affinity and selective agonists with biological efficacy were identified through iterative cycles of a structure-based design strategy encompassing computational methods, chemistry, and preclinical pharmacology. 1,2,4-Triazole derivatives of our previously reported hit (4) showed enhanced SST4 binding affinity, activity, and selectivity. Thirty-five compounds showed low nanomolar range SST4 binding affinity, 12 having a Ki 500-fold affinity for SST4 as compared to SST2A. SST4 activities were consistent with the respective SST4 binding affinities (EC50 600-fold selectivity over SST2A) display a favorable physiochemical profile, and was advanced to learning and memory behavior evaluations in the senescence accelerated mouse-prone 8 model of AD-related cognitive decline. Chronic administration enhanced learning with i.p. dosing (1 mg kg-1) compared to vehicle. Chronic administration enhanced memory with both i.p. (0.01, 0.1, 1 mg kg-1) and oral (0.01, 10 mg kg-1) dosing compared to vehicle. This study identified a novel series of SST4 agonists with high affinity, selectivity, and biological activity that may be useful in the treatment of AD. This journal is

3,4,5-TRISUBSTITUTED-1,2,4-TRIAZOLES AND 3,4,5-TRISUBSTITUTED-3-THIO-1,2,4-TRIAZOLES AND USES THEREOF

The present disclosure describes novel compounds that are somatostatin receptor type 4 agonists.

Thiadiazole-based Thioglycosides as Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors

A series of thiadiazole-based thioglycosides were synthesized as SGLT2 inhibitors from D-glucose, D-galactose and a variety of phenylacetic acids via a convenient protocol in 8 steps and evaluated in vivo with an oral glucose tolerance test (OGTT), and 5-benzyl-1,3,4-thiadiazol-2-yl 1-thio-β-D-glucopyranoside (1a) was the most efficacious to suppress the blood glucose excursion during OGTT.